It's neither good or bad...just an accounting issue.The question...

It's neither good or bad...just an accounting issue.

The question whether it's good or bad will be answered on what they intend to do with this subsidary (ie spin-off, listing etc.) and the deals they can strike with pharma's.

I think the way that any potential licensing deal is structured will be the key (ie per vaccine, human, vet, etc. and the amount they are willing to pay for it).

Nothing has changed IMO from where NAL was sitting last week...